Albany Molecular Research Inc. (AMRI) said today it will partner with Multispan to co-market their G protein-coupled receptor (GPCR) drug discovery services to global biopharma companies.
Under the companies’ three-year agreement, AMRI gains access to Multispan's GPCR cell lines, assay capabilities, and expertise. Multispan will make available to its customers AMRI's global integrated drug discovery solutions, including high-throughput screening (HTS) and discovery medicinal chemistry.
Focusing exclusively on drug discovery research targeting GPCRs, Multispan has created what it calls the industry's largest collection of human GPCR clones and GPCR-expressing cell lines for HTS including the HExTM series of High Expression cell lines.
“Multispan has an impressive collection of human GPCR clones and GPCR-expressing cell lines for HTS, which will be beneficial to AMRI's integrated drug discovery efforts,” Rory Curtis, Ph.D., vp, discovery biology and pharmacology, and site head of AMRI Buffalo, said in a statement.
Multispan also offers custom compound profiling, cell-line generation, antibody development, and frozen cell and membrane preparation, with scientific consultations from assay design to implementation.
AMRI, a global contract research and manufacturing organization, said the agreement was aimed at boosting its success in GPCR drug discovery. The partnership is also an example, the company said, of the local and national partnerships it seeks to create that combine its HTS and analytic informatics with validated assays and technologies.
On Monday, AMRI launched the Drug Discovery Center in Buffalo, NY, on the Buffalo Niagara Medical Campus. The facility is designed to foster partnerships and advance translational medicine offer HTS, medicinal chemistry and pharmacology within a single U.S. site.
“We are eager for our customers to have access to the leading-edge capabilities for drug discovery that AMRI's new center in Buffalo offers across biology and medicinal chemistry,” added Multispan CEO Helena Mancebo.